دورية أكاديمية
Deployment of novel oral polio vaccine type 2 under emergency use listing in Nigeria: the rollout experience.
| العنوان: | Deployment of novel oral polio vaccine type 2 under emergency use listing in Nigeria: the rollout experience. |
|---|---|
| المؤلفون: | Asekun A; US Centers for Disease Control and Prevention, Georgia, United States of America., Nkwogu L; World Health Organization, Abuja, Nigeria., Bawa S; World Health Organization, Abuja, Nigeria., Usman S; CORE Group Polio Project, Abuja, Nigeria., Edukugho A; African Field Epidemiology Network, Abuja, Nigeria., Ocheh J; World Health Organization, Abuja, Nigeria., Banda R; World Health Organization, Abuja, Nigeria., Nganda GW; US Centers for Disease Control and Prevention, Georgia, United States of America., Nsubuga P; National Primary Health Care Development Agency, Abuja, Nigeria., Archer R; US Centers for Disease Control and Prevention, Georgia, United States of America., Nebechukwu T; Rotary International, Abuja, Nigeria., Mohammed A; Global Public Health Solutions, Georgia, United States of America., Shuaib F; Rotary International, Abuja, Nigeria., Bolu O; US Centers for Disease Control and Prevention, Georgia, United States of America., Adamu U; Rotary International, Abuja, Nigeria. |
| المصدر: | The Pan African medical journal [Pan Afr Med J] 2023 Jul 13; Vol. 45 (Suppl 2), pp. 3. Date of Electronic Publication: 2023 Jul 13 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet ISSN: 1937-8688 (Electronic) NLM ISO Abbreviation: Pan Afr Med J Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Kampala, Uganda : African Field Epidemiology Network |
| مواضيع طبية MeSH: | Poliomyelitis*/prevention & control , Poliomyelitis*/epidemiology , Poliovirus*, Humans ; Poliovirus Vaccine, Oral ; Nigeria/epidemiology ; Global Health ; Disease Outbreaks/prevention & control |
| مستخلص: | In 2011, a dedicated consortium of experts commenced work on the development of the novel oral poliovirus vaccine type 2 (nOPV2). After careful and rigorous analysis of data to enable early, targeted use of the vaccine, World Health Organization´s (WHO´s) Strategic Advisory Group of Experts on Immunization (SAGE) reviewed data from accelerated clinical development of nOPV2 and endorsed entering assessment under WHO´s Emergency Use Listing (EUL) procedure. In November 2020, nOPV2 received an interim recommendation for use under EUL to enable rapid field availability and potential wider rollout of the vaccine. In December 2020, Nigeria initiated preparation to meet all criteria for initial use of nOPV2 in the country and the documentation process to verify meeting them. The process entailed addressing the status of meeting 25 readiness criteria in nine categories for nOPV2 use in Nigeria for response efforts to ongoing cVDPV2 outbreaks. During January-February 2021, Nigeria submitted the required documentation for all required indicators for nOPV2 initial use. In February 2021, the country obtained approval from the GPEI nOPV2 Readiness Verification Team to introduce nOPV2 and in March 2021, rolled out the novel vaccine in mass vaccination campaigns for outbreak response in Bayelsa, Delta, Niger, Sokoto and Zamfara states, and one area council in the Federal Capital Territory (FCT). The lessons learned from this rollout experience in Nigeria are being applied as the country streamlines and strengthens the nOPV2 rollout process across the remaining states. Competing Interests: The authors declare no competing interests. (©Adeyelu Asekun et al.) |
| References: | Cell Host Microbe. 2020 May 13;27(5):736-751.e8. (PMID: 32330425) Hum Vaccin Immunother. 2020 May 3;16(5):1208-1214. (PMID: 31464551) J Infect Dis. 2011 Apr 1;203(7):898-909. (PMID: 21402542) BMC Public Health. 2020 Aug 12;20(Suppl 2):1177. (PMID: 32787897) NPJ Vaccines. 2020 Mar 20;5(1):26. (PMID: 32218998) Vaccine X. 2020 May 06;5:100067. (PMID: 32462141) Risk Anal. 2021 Feb;41(2):329-348. (PMID: 33174263) J Infect Dis. 2016 May 1;213 Suppl 3:S67-72. (PMID: 26609004) Vaccine. 2018 Mar 20;36(13):1766-1771. (PMID: 29477307) |
| معلومات مُعتمدة: | 001 International WHO_ World Health Organization |
| فهرسة مساهمة: | Keywords: Nigeria; Prevalence; antibodies; disease outbreaks; immunity; immunization; oral; polio virus vaccine; poliomyelitis; risk factors; serotype |
| المشرفين على المادة: | 0 (Poliovirus Vaccine, Oral) |
| تواريخ الأحداث: | Date Created: 20240219 Date Completed: 20240220 Latest Revision: 20240420 |
| رمز التحديث: | 20240420 |
| مُعرف محوري في PubMed: | PMC10874098 |
| DOI: | 10.11604/pamj.supp.2023.45.2.38033 |
| PMID: | 38370105 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1937-8688 |
|---|---|
| DOI: | 10.11604/pamj.supp.2023.45.2.38033 |